Amgen small cell lung cancer treatment granted FDA orphan status

Amgen’s bispecific T-cell engager antibody was granted orphan designation by the FDA as a treatment of small cell lung cancer, according to a post to the agency’s website
https://thefly.com/landingPageNews.php?id=2841655